US Stock MarketDetailed Quotes
NRXP NRX Pharmaceuticals
- 1.9001
- -0.1499-7.31%
Close Aug 13 16:00 ET
20.33MMarket Cap-616P/E (TTM)
2.1400High1.9000Low241.36KVolume1.9300Open2.0500Pre Close485.47KTurnover3.07%Turnover RatioLossP/E (Static)10.70MShares7.333052wk High-1.35P/B14.92MFloat Cap1.900052wk Low--Dividend TTM7.85MShs Float769.9000Historical High--Div YieldTTM11.71%Amplitude1.9000Historical Low2.0110Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
NRX Pharmaceuticals Stock Forum
Set ready
Hope Therapeutics, Inc. and NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announce Alignment With FDA on Pediatric Study Plan for NRX-100 (Ketamine)
loading zone
NRX Pharmaceuticals (Nasdaq:Nrxp) to Proceed With Two New Drug Applications in 2024; NRX-101 Has Been Returned to the Company for Filing
What is OCU400's market potential? If we take Ocugen's estimates seriously, it is mouthwatering. The biotech projects that OCU400 could earn approval in 2026. Ocugen thinks the therapy could generate between $30 billion and $47 billion in total revenue in the five years after approval. The company's market cap is about $488 million as of this writing. So by any standar...
No comment yet